Us Pancreatic Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
U.S. Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
U.S. Pancreatic Cancer Diagnostics Market Analysis and Insights
The growing prevalence of pancreatic cancer as well as the increasing need for diagnostic products for these conditions have enhanced the market demand. The advancement in technology for easy supply of products and fast manufacturing facilities are also attributing to market growth. The major market players are highly focused on product launches and product approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players with product approval due to surging emergence.
The U.S. pancreatic cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of leukemia diagnosis and development is expected to further boost the market growth.
However, difficulties in leukemia screening techniques are expected to restrain market growth in the forecast period. Increasing healthcare expenditure on cancer diagnosis and treatment are expected to give opportunities to the market to enhance the treatment. The improvement in awareness about regular healthcare checkups, upcoming diagnostic centers, and advancements in diagnostic methods for pancreatic cancer and technological developments is expected to boost the market growth. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products and instruments is expected to challenge market growth.
The U.S. pancreatic cancer diagnostics market is supportive and aims to reduce the disease thereby improving the recovery and performance of individuals. Data Bridge Market Research analyzes that the U.S. pancreatic cancer diagnostics market will grow at a CAGR of 8.3% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2020 – 2015) |
|
Quantitative Units |
Revenue in USD Million and Pricing in USD |
|
Segments Covered |
By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Regions Covered |
Southern U.S., Western U.S., Mid-Western U.S., and North-Eastern U.S. |
|
Market Players Covered |
Agilent Technologies, Inc., BD, Biological Dynamics, CANON MEDICAL SYSTEMS CORPORATION, ClearNote Health, CTK Biotech, Inc., Danaher., Exact Sciences Corporation, F. Hoffman- La Roche Ltd, FUJIFILM Holdings America Corporation, GRAIL, Immunovia, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, MP BIOMEDICALS, Myriad Genetics, Inc., QIAGEN, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. among others |
Market Definition
Pancreatic cancer is fatal, and the diagnosis process of pancreatic cancer also has safety issues. It is not cost-effective. One of the costliest medical disorders to treat cancer. Cancer patients may be hospitalized and receive a variety of therapies for tumors, such as surgery, radiation treatment, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising. Diagnosis of pancreatic cancer includes ultrasound, biopsy procedures, and blood tests. Pancreatic cancer is one of the leading causes of death worldwide, and the prevalence of this disease has increased at an alarming rate. The cancer is confined to the top layers of pancreatic duct cells and has not invaded deeper tissues. It has not spread outside of the pancreas. These tumors are sometimes referred to as carcinoma in situ. It has not spread to nearby lymph nodes or to distant sites.
Pancreatic cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Pancreatic cancer is the eighth most common cancer in women and the tenth most common cancer in men. Incidence rates of pancreatic cancer have gone up by around 1% each year. It occurs less frequently. It is slightly more common among women than men, however, the average lifetime risk of getting pancreatic cancer in both sexes is about ½ of 1% on average. However, the High cost associated with the treatment and diagnostic procedure is expected to restrain the market growth.
U.S. Pancreatic Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:
DRIVERS
- Increasing Prevalence of Pancreatic Cancer
All ages can be affected by this type of cancer. Pancreatic cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Pancreatic cancer is the eighth most common cancer in women and the tenth most common cancer in men. Incidence rates of pancreatic cancer have gone up by around 1% each year. It occurs less frequently. It is slightly more common among women than men, however, the average lifetime risk of getting pancreatic cancer in both sexes is about ½ of 1% on average. These conditions include abdominal pain, loss of appetite or unintended weight loss, yellowing of the skin and the whites of the eyes (jaundice), light-colored stools, dark-colored urine, and itchy skin. It is the eighth most common type of cancer diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. Due to various risk factors, pancreatic cancer incidence has been becoming a significant socio-economic issue. This is expected to act as a driver for market growth.
- Novel Technological Advancements for Pancreatic Cancer
Pancreatic cancer is seldom detected at its early stages when it is most curable. This is because it often does not cause symptoms until after it has spread to other organs. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis. The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the pancreatic disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing pancreatic cancer classification algorithms.
The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of pancreatic cancer is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged which is deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize blood pictures automatically. Advancement in pancreatic cancer diagnostic methods has become a well-accepted technology allowing high-quality diagnostic tests. The development of several new diagnostic methods will increase the market growth as many new and advanced products are launched. Hence, it is expected to create demand for pancreatic cancer diagnostic products in the market.
OPPORTUNITY
- Rising Healthcare Expenditure for Cancer Diagnosis and Treatment
Across the globe, R&D activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to increase the demand for pancreatic cancer diagnostics. Increasing the healthcare expenditure for pancreatic cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is expected to act as an opportunity for market growth.
Henceforth, the rising healthcare expenditure is positively associated with product development, product registration, and product launch. Thus, the rising healthcare expenditure and government support are further expected to drive market growth in the coming years. The increase in healthcare expenditure also impacts the increasing implementation of advanced cancer diagnostic products and better treatment for cancer patients. For this reason, increasing healthcare expenditure for pancreatic cancer treatment is projected to act as an opportunity for market growth.
RESTRAINT/CHALLENGE
- Late Diagnosis and Poor Prognosis of Pancreatic Cancer
Late diagnosis of the disease is due to the increasing number of pancreatic cancer tumors which do not respond well to commonly used cancer therapies as other, less lethal types of cancer. But there are treatment options, including surgery, chemotherapy, and radiation. There are different types of pancreatic cancer. Most pancreatic cancers are the exocrine type. This means that they start in cells that produce pancreatic digestive juices. About 30% of patients are smokers, and 5% have a history of pancreatitis, an inflammation of the pancreas, which can be caused by stones or heavy alcohol intake.
Cancer is the leading cause of death worldwide. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is a lack of public knowledge of early cancer signs, especially if such symptoms are unusual. The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to act as a restraint for market growth.
Post-COVID-19 Impact on U.S. Pancreatic Cancer Diagnostics Market
COVID-19 has negatively affected the market growth as patients suffering from pancreatic cancer postponed their surgery due to a rapid surge in COVID-19 cases across geographies. Additionally, people having pancreatic cancer were at risk of becoming severely ill. The fear of coronavirus infection affected the market growth amid the pandemic.
Recent Developments
- In December 2022, FUJIFILM Holdings America Corporation announced the company has a purchase agreement asset with Inspirata, Inc. to acquire a digital pathology business to expand its robust enterprise imaging offering. This results in enabling the integration of pathology images and data into a healthcare organization’s electronic health record system to streamline care delivery for oncology patients
- In August 2020, Siemens Healthcare GmbH announced that it has entered into an agreement with Varian Medical Systems, Inc. With this acquisition, Siemens Healthcare GmbH has helped in developing advanced solutions to treat cancer and strengthen its position in the healthcare industry
- In May 2020, F. Hoffmann- La Roche Ltd announced that it has acquired Stratos Genomics. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus, leading to more revenue generation for the company.
U.S. Pancreatic Cancer Diagnostics Market Scope
The U.S. pancreatic cancer diagnostics market is segmented into eight notable segments based on test type, cancer stages, tumor type, product, application, technology, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Test Type
- Imaging Test
- Biopsy
- Blood Test
- Genomic Test
- Others
On the basis of test type, the market is segmented into imaging test, biopsy, blood test, genomic test, and others.
Cancer Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
On the basis of cancer stages, the market is segmented into stage 0, stage I, stage II, stage III, and stage IV.
Tumor Type
- Exocrine Tumors
- Neuroendocrine Tumors
On the basis of tumor type, the market is segmented into exocrine tumors and neuroendocrine tumors.
Product
- Instrument-Based Products
- Platform-Based Products
- Kits and Reagents
- Other Consumables
On the basis of product, the market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables.
Application
- Screening
- Diagnostic And Predictive
- Prognostic
- Research
On the basis of application, the market is segmented into screening, diagnostic and predictive, prognostic, and research.
Technology
- Fluorescent In Situ Hybridization
- Next Generation Sequencing
- Fluoroimmunoassay
- Comparative Genomic Hybridization
- Immunohistochemical
- Others
On the basis of technology, the market is segmented into fluorescent in situ hybridization, next generation sequencing, fluoroimmunoassay, comparative genomic hybridization, immunohistochemical, and others.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Academic Institutes
- Ambulatory Surgical Centers
- Others
On the basis of end user, the market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.
U.S. Pancreatic Cancer Diagnostics Market Country Analysis/Insights
The U.S. pancreatic cancer diagnostics market is analyzed, and market size insights and trends are provided by the test type, cancer stages, tumor type, product, application, technology, end user, and distribution channel as referenced above.
The regions covered in the market are Southern U.S., Western U.S., Mid-Western U.S., and North-Eastern U.S.
The Southern U.S. pancreatic cancer diagnostics market is expected to grow due to the rise in the prevalence and incidence of pancreatic cancer and the increase in awareness about pancreatic cancer diagnostics. These are the key contributing factors which is expected to boost the market growth in the country.
The region section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of U.S. brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and U.S. Pancreatic Cancer Diagnostics Market Share Analysis
The U.S. pancreatic cancer diagnostics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the U.S. pancreatic cancer diagnostics market are Agilent Technologies, Inc., BD, Biological Dynamics, CANON MEDICAL SYSTEMS CORPORATION, ClearNote Health, CTK Biotech, Inc., Danaher., Exact Sciences Corporation, F. Hoffman- La Roche Ltd, FUJIFILM Holdings America Corporation, GRAIL, Immunovia, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, MP BIOMEDICALS, Myriad Genetics, Inc., QIAGEN, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 U.S. CHRONIC PANCREATITIS TESTING MARKET
4.1 CHRONIC PANCREATITIS
4.2 LABORATORY TESTING
4.3 CHRONIC PANCREATITIS DIAGNOSE
4.4 PANCREATIC FUNCTION TESTS
4.4.1 INDIRECT PANCREATIC FUNCTION TESTS
4.4.2 DIRECT PANCREATIC FUNCTION TESTS
5 PREMIUM INSIGHTS
5.1 PESTEL MODEL
5.2 PORTER'S FIVE FORCES
5.3 EPIDEMIOLOGY
6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS
7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWTH IN THE PREVALENCE OF PANCREATIC CANCER
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER
8.2 RESTRAINTS
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER
8.3 OPPORTUNITIES
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS
8.4 CHALLENGES
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
9 IMPACT OF COVID-19
9.1 OVERVIEW
9.2 DEMAND SURGE FOR MEDICAL DIAGNOSTIC
9.3 GROWTH IN GOVERNMENT SPENDING ON HEALTHCARE
9.4 STRATEGIC INITIATIVES BY KEY PLAYERS
9.5 INCREASE IN THE PRICE OF TESTS KITS AND REAGENTS
10 OUTLOOK AND TREND OF THE MARKET AFTER COVID -19
11 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE
11.1 OVERVIEW
11.2 IMAGING TEST
11.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
11.2.2 MAGNETIC RESONANCE IMAGING (MRI)
11.2.3 MR CHOLANGIOPANCREATOGRAPHY
11.2.4 MR ANGIOGRAPHY (MRA)
11.3 ULTRASOUND
11.3.1 ABDOMINAL ULTRASOUND
11.3.2 ENDOSCOPIC ULTRASOUND (EUS)
11.4 CHOLANGIOPANCREATOGRAPHY
11.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)
11.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)
11.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC)
11.5 POSITRON EMISSION TOMOHRAPHY (PET)
11.6 OTHERS
11.7 BIOPSY
11.8 CT-GUIDED NEEDLE BIOPSY
11.9 FINE NEEDLE ASPIRATION (FNA)
11.1 CORE NEEDLE BIOPSY
11.11 OTHERS
11.12 BLOOD TEST
11.13 LIVER FUNCTION TEST
11.14 TUMOR MARKER
11.14.1 CA 19-9 BIOMARKER TEST
11.14.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST
11.14.3 CA 50 MARKER TEST
11.14.4 OTHERS
11.15 OTHERS
11.16 GENOMIC TEST
11.17 OTHERS
12 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
12.1 OVERVIEW
12.2 STAGE IV
12.3 STAGE III
12.4 STAGE II
12.4.1 STAGE IIA
12.4.2 STAGE IIB
12.5 STAGE I
12.5.1 STAGE IB
12.5.2 STAGE IA
12.6 STAGE 0
13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
13.1 OVERVIEW
13.2 EXOCRINE TUMORS
13.2.1 INSTRUMENT-BASED PRODUCTS
13.2.2 PLATFORM-BASED PRODUCTS
13.2.3 KITS AND REAGENTS
13.2.4 OTHER CONSUMABLES
13.3 NEUROENDOCRINE TUMORS
13.3.1 INSTRUMENT-BASED PRODUCTS
13.3.2 PLATFORM-BASED PRODUCTS
13.3.3 KITS AND REAGENTS
13.3.4 OTHER CONSUMABLES
14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT
14.1 OVERVIEW
14.2 INSTRUMENT-BASED PRODUCTS
14.2.1 IMAGING
14.2.2 BIOPSY
14.3 PLATFORM-BASED PRODUCTS
14.3.1 NEXT-GENERATION SEQUENCING
14.3.2 MICROARRAYS
14.3.3 PCR
14.3.4 OTHERS
14.4 KITS AND REAGENTS
14.4.1 CA19-9 PANCREATIC CANCER TEST KITS
14.4.1.1 ELISA TEST KITS
14.4.1.2 CASETTE TEST KITS
14.4.1.3 OTHERS
14.4.2 CEA PANCREATIC CANCER TEST KITS
14.4.2.1 ELISA TEST KITS
14.4.2.2 CASETTE TEST KITS
14.4.2.3 OTHERS
14.5 OTHERS
15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
15.1 OVERVIEW
15.2 FLUORESCENT IN SITU HYBRIDIZATION
15.3 NEXT GENERATION SEQUENCING
15.4 FLUORIMMUNOASSAY
15.5 COMPARATIVE GENOMIC HYBRIDIZATION
15.6 IMMUNOHISTOCHEMICAL
15.7 OTHERS
16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION
16.1 OVERVIEW
16.2 SCREENING
16.2.1 INSTRUMENT-BASED PRODUCTS
16.2.2 PLATFORM-BASED PRODUCTS
16.2.3 KITS AND REAGENTS
16.2.4 OTHER CONSUMABLES
16.3 DIAGNOSTIC AND PREDICTIVE
16.3.1 INSTRUMENT-BASED PRODUCTS
16.3.2 PLATFORM-BASED PRODUCTS
16.3.3 KITS AND REAGENTS
16.3.4 OTHER CONSUMABLES
16.4 PROGNOSTIC
16.4.1 INSTRUMENT-BASED PRODUCTS
16.4.2 PLATFORM-BASED PRODUCTS
16.4.3 KITS AND REAGENTS
16.4.4 OTHER CONSUMABLES
16.5 RESEARCH
16.5.1 INSTRUMENT-BASED PRODUCTS
16.5.2 PLATFORM-BASED PRODUCTS
16.5.3 KITS AND REAGENTS
16.5.4 OTHER CONSUMABLES
17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 DIAGNOSTIC CENTERS
17.4 CANCER RESEARCH CENTERS
17.5 ACADEMIC INSTITUTES
17.6 AMBULATORY SURGICAL CENTERS
17.7 OTHERS
18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 DIRECT TENDER
18.3 RETAIL SALES
18.4 OTHERS
19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION
19.1 OVERVIEW
19.2 U.S.
19.3 SOUTHERN U.S.
19.3.1 FLORIDA
19.3.2 TEXAS
19.3.3 NORTH CAROLINA
19.3.4 GEORGIA
19.3.5 VIRGINIA
19.3.6 TENNESSEE
19.3.7 REST OF SOUTHERN U.S.
19.4 WESTERN U.S.
19.4.1 ILLINOIS
19.4.2 OHIO
19.4.3 MICHIGAN
19.4.4 INDIANA
19.4.5 MISSOURI
19.4.6 MINNESOTA
19.4.7 REST OF WESTERN U.S.
19.5 MID-WESTERN U.S.
19.5.1 CALIFORNIA
19.5.2 WASHINGTON
19.5.3 ARIZONA
19.5.4 COLORADO
19.5.5 OREGON
19.5.6 NEVADA
19.5.7 REST OF MID-WESTERN U.S.
19.6 NORTH-EASTERN U.S.
19.6.1 NEW YORK
19.6.2 PENNSYLVANIA
19.6.3 NEW JERSEY
19.6.4 MASSACHUSETTS
19.6.5 MARYLAND
19.6.6 CONNECTICUT
19.6.7 REST OF NORTH-EASTERN U.S.
20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: EUROPE
21 SWOT ANALYSIS
22 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET
22.1 F. HOFFMANN- LA ROCHE LTD
22.1.1 COMPANY SNAPSHOT
22.1.2 SWOT
22.1.3 REVENUE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENT
22.2 KONINKLIJKE PHILIPS N.V.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 PRODUCT PORTFOLIO
22.2.4 RECENT DEVELOPMENTS
22.3 CANON MEDICAL SYSTEMS CORPORATION
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 PRODUCT PORTFOLIO
22.3.4 RECENT DEVELOPMENT
22.4 GRAIL
22.4.1 COMPANY PROFILE
22.4.2 PRODUCT PORTFOLIO
22.4.3 RECENT DEVELOPMENT
22.5 SIEMENS HEALTHCARE GMBH
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENT
22.6 AGILENT TECHNOLOGIES, INC.
22.6.1 COMPANY PROFILE
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 BIOLOGICAL DYNAMICS
22.7.1 COMPANY SNAPSHOT
22.7.2 SWOT
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 BD
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 CLEARNOTE HEALTH
22.9.1 COMPANY SNAPSHOT
22.9.2 SWOT
22.9.3 PRODUCT PORTFOLIO
22.9.4 RECENT DEVELOPMENT
22.1 CTK BIOTECH, INC.
22.10.1 COMPANY PROFILE
22.10.2 PRODUCT PORTFOLIO
22.10.3 RECENT DEVELOPMENT
22.11 DANAHER.
22.11.1 COMPANY SNAPSHOT
22.11.2 SWOT
22.11.3 REVENUE ANALYSIS
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 EXACT SCIENCES CORPORATION
22.12.1 COMPANY SNAPSHOT
22.12.2 SWOT
22.12.3 REVENUE ANALYSIS
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENT
22.13 FUJIFILM HOLDINGS AMERICA CORPORATION
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 IMMUNOVIA
22.14.1 COMPANY SNAPSHOT
22.14.2 SWOT
22.14.3 REVENUE ANALYSIS
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENT
22.15 LABORATORY CORPORATION OF AMERICA HOLDINGS
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MP BIOMEDICALS.
22.16.1 COMPANY PROFILE
22.16.2 PRODUCT PORTFOLIO
22.16.3 RECENT DEVELOPMENT
22.17 MYRIAD GENETICS, INC.
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENT
22.18 QIAGEN
22.18.1 COMPANY SNAPSHOT
22.18.2 REVENUE ANALYSIS
22.18.3 PRODUCT PORTFOLIO
22.18.4 RECENT DEVELOPMENT
22.19 QUEST DIAGNOSTICS INCORPORATED
22.19.1 COMPANY SNAPSHOT
22.19.2 SWOT
22.19.3 REVENUE ANALYSIS
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPMENT
22.2 THERMO FISHER SCIENTIFIC INC.
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENT
23 QUESTIONNAIRE
24 RELATED REPORTS
List of Table
TABLE 1 U.S. CHRONIC PANCREATITIS TESTING: BY BLOOD MARKERS (NO. OF PATIENTS, TYPE OF TESTS TAKEN DURING TREATMENT
TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER
TABLE 2 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 11 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 12 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 14 U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 15 U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 17 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 18 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 19 U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 20 U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 21 U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 22 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 23 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 24 U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 25 U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 27 U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 29 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 30 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 32 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 33 SOUTHERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 34 SOUTHERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 35 SOUTHERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 SOUTHERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 SOUTHERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 SOUTHERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 39 SOUTHERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 40 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 41 SOUTHERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 42 SOUTHERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 43 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 44 SOUTHERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 45 SOUTHERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 46 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 47 SOUTHERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 48 SOUTHERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 49 SOUTHERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 50 SOUTHERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 51 SOUTHERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 52 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 54 SOUTHERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 55 SOUTHERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 56 SOUTHERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 57 SOUTHERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 58 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 60 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 FLORIDA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 FLORIDA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 FLORIDA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 FLORIDA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 FLORIDA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 FLORIDA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 FLORIDA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 69 FLORIDA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 70 FLORIDA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 71 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 72 FLORIDA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 73 FLORIDA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 74 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 75 FLORIDA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 76 FLORIDA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 77 FLORIDA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 78 FLORIDA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 79 FLORIDA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 80 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 82 FLORIDA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 83 FLORIDA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 FLORIDA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 FLORIDA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 86 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 TEXAS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 TEXAS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 TEXAS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 TEXAS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 TEXAS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 TEXAS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 TEXAS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 97 TEXAS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 98 TEXAS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 99 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 100 TEXAS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 101 TEXAS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 102 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 103 TEXAS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 104 TEXAS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 105 TEXAS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 106 TEXAS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 TEXAS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 108 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 109 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 TEXAS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 TEXAS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 112 TEXAS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 TEXAS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 117 NORTH CAROLINA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 NORTH CAROLINA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 119 NORTH CAROLINA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 120 NORTH CAROLINA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 NORTH CAROLINA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 NORTH CAROLINA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 NORTH CAROLINA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 125 NORTH CAROLINA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 126 NORTH CAROLINA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 127 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 128 NORTH CAROLINA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 NORTH CAROLINA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 130 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 131 NORTH CAROLINA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 132 NORTH CAROLINA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 133 NORTH CAROLINA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 NORTH CAROLINA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 135 NORTH CAROLINA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 136 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 137 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 NORTH CAROLINA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 139 NORTH CAROLINA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 140 NORTH CAROLINA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 141 NORTH CAROLINA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 143 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 144 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 GEORGIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 GEORGIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 GEORGIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 GEORGIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 GEORGIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 GEORGIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 GEORGIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 153 GEORGIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 154 GEORGIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 155 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 156 GEORGIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 GEORGIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 GEORGIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 GEORGIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 161 GEORGIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 162 GEORGIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 163 GEORGIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 164 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 165 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 GEORGIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 167 GEORGIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 GEORGIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 169 GEORGIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 170 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 171 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 172 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 173 VIRGINIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 VIRGINIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 VIRGINIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 VIRGINIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 VIRGINIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 VIRGINIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 179 VIRGINIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 180 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 181 VIRGINIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 182 VIRGINIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 183 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 184 VIRGINIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 VIRGINIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 186 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 187 VIRGINIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 188 VIRGINIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 189 VIRGINIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 190 VIRGINIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 191 VIRGINIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 193 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 VIRGINIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 VIRGINIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 196 VIRGINIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 VIRGINIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 198 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 201 TENNESSEE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 202 TENNESSEE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 203 TENNESSEE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 TENNESSEE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 205 TENNESSEE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 TENNESSEE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 TENNESSEE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 208 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 209 TENNESSEE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 210 TENNESSEE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 TENNESSEE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 212 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 213 TENNESSEE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 214 TENNESSEE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 215 TENNESSEE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 TENNESSEE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 TENNESSEE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 219 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 220 TENNESSEE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 221 TENNESSEE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 222 TENNESSEE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 223 TENNESSEE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 224 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 225 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 226 REST OF SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 228 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 WESTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 WESTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 WESTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 WESTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 233 WESTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 234 WESTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 235 WESTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 236 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 237 WESTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 238 WESTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 239 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 240 WESTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 WESTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 WESTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 243 WESTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 244 WESTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 245 WESTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 246 WESTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 247 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 248 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 249 WESTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 250 WESTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 251 WESTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 252 WESTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 253 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 254 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 255 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 256 ILLINOIS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 257 ILLINOIS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 258 ILLINOIS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 259 ILLINOIS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 260 ILLINOIS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 ILLINOIS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 ILLINOIS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 263 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 264 ILLINOIS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 265 ILLINOIS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 266 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 267 ILLINOIS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 ILLINOIS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 ILLINOIS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 ILLINOIS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 272 ILLINOIS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 273 ILLINOIS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 274 ILLINOIS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 275 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 276 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 277 ILLINOIS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 278 ILLINOIS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 279 ILLINOIS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 280 ILLINOIS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 281 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 282 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 284 OHIO IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 285 OHIO MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 286 OHIO ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 287 OHIO CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 288 OHIO BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 289 OHIO TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 290 OHIO BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 291 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 292 OHIO STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 293 OHIO STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 294 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 295 OHIO EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 OHIO NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 298 OHIO INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 299 OHIO PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 300 OHIO KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 301 OHIO CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 302 OHIO CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 303 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 304 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 305 OHIO SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 306 OHIO DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 307 OHIO PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 308 OHIO RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 309 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 310 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 311 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 312 MICHIGAN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 313 MICHIGAN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 314 MICHIGAN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 315 MICHIGAN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 316 MICHIGAN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 317 MICHIGAN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 318 MICHIGAN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 319 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 320 MICHIGAN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 321 MICHIGAN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 322 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 323 MICHIGAN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 324 MICHIGAN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 MICHIGAN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 MICHIGAN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 MICHIGAN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 MICHIGAN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 330 MICHIGAN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 331 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 332 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 333 MICHIGAN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 334 MICHIGAN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 335 MICHIGAN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 336 MICHIGAN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 337 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 338 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 339 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 340 INDIANA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 341 INDIANA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 342 INDIANA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 343 INDIANA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 344 INDIANA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 345 INDIANA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 346 INDIANA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 347 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 348 INDIANA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 349 INDIANA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 350 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 351 INDIANA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 352 INDIANA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 353 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 INDIANA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 INDIANA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 INDIANA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 357 INDIANA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 358 INDIANA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 359 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 360 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 361 INDIANA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 362 INDIANA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 363 INDIANA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 364 INDIANA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 365 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 366 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 367 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 368 MISSOURI IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 369 MISSOURI MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 370 MISSOURI ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 371 MISSOURI CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 372 MISSOURI BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 373 MISSOURI TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 374 MISSOURI BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 375 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 376 MISSOURI STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 377 MISSOURI STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 378 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 379 MISSOURI EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 380 MISSOURI NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 381 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 382 MISSOURI INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 383 MISSOURI PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 MISSOURI KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 385 MISSOURI CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 386 MISSOURI CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 387 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 388 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 MISSOURI SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 390 MISSOURI DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 391 MISSOURI PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 392 MISSOURI RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 393 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 394 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 395 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 396 MINNESOTA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 397 MINNESOTA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 398 MINNESOTA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 399 MINNESOTA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 400 MINNESOTA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 401 MINNESOTA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 402 MINNESOTA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 403 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 404 MINNESOTA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 405 MINNESOTA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 406 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 407 MINNESOTA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 408 MINNESOTA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 409 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 410 MINNESOTA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 411 MINNESOTA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 412 MINNESOTA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 413 MINNESOTA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 MINNESOTA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 416 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 417 MINNESOTA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 418 MINNESOTA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 419 MINNESOTA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 420 MINNESOTA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 421 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 422 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 423 REST OF WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 424 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 425 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 426 MID-WESTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 427 MID-WESTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 428 MID-WESTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 429 MID-WESTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 430 MID-WESTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 431 MID-WESTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 432 MID-WESTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 433 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 434 MID-WESTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 435 MID-WESTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 436 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 437 MID-WESTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 438 MID-WESTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 439 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 440 MID-WESTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 MID-WESTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 442 MID-WESTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 443 MID-WESTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 444 MID-WESTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 445 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 446 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 447 MID-WESTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 448 MID-WESTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 449 MID-WESTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 450 MID-WESTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 451 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 452 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 453 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 454 CALIFORNIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 455 CALIFORNIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 456 CALIFORNIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 457 CALIFORNIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 458 CALIFORNIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 459 CALIFORNIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 460 CALIFORNIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 461 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 462 CALIFORNIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 463 CALIFORNIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 464 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 465 CALIFORNIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 466 CALIFORNIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 467 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 468 CALIFORNIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 469 CALIFORNIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 470 CALIFORNIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 471 CALIFORNIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 472 CALIFORNIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 473 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 474 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 CALIFORNIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 476 CALIFORNIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 477 CALIFORNIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 478 CALIFORNIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 479 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 480 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 481 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 482 WASHINGTON IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 483 WASHINGTON MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 484 WASHINGTON ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 485 WASHINGTON CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 486 WASHINGTON BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 487 WASHINGTON TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 488 WASHINGTON BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 489 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 490 WASHINGTON STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 491 WASHINGTON STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 492 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 493 WASHINGTON EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 494 WASHINGTON NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 495 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 496 WASHINGTON INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 497 WASHINGTON PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 498 WASHINGTON KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 499 WASHINGTON CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 500 WASHINGTON CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 501 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 502 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 503 WASHINGTON SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 504 WASHINGTON DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 505 WASHINGTON PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 506 WASHINGTON RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 507 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 508 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 509 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 510 ARIZONA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 511 ARIZONA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 512 ARIZONA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 513 ARIZONA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 514 ARIZONA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 515 ARIZONA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 516 ARIZONA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 517 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 518 ARIZONA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 519 ARIZONA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 520 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 521 ARIZONA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 522 ARIZONA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 523 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 524 ARIZONA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 525 ARIZONA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 526 ARIZONA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 527 ARIZONA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 528 ARIZONA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 529 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 530 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 531 ARIZONA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 532 ARIZONA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 533 ARIZONA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 534 ARIZONA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 535 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 536 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 537 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 538 COLORADO IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 539 COLORADO MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 540 COLORADO ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 541 COLORADO CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 542 COLORADO BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 543 COLORADO TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 544 COLORADO BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 545 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 546 COLORADO STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 547 COLORADO STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 548 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 549 COLORADO EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 550 COLORADO NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 551 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 552 COLORADO INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 553 COLORADO PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 554 COLORADO KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 555 COLORADO CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 556 COLORADO CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 557 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 558 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 559 COLORADO SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 560 COLORADO DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 561 COLORADO PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 562 COLORADO RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 563 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 564 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 565 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 566 OREGON IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 567 OREGON MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 568 OREGON ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 569 OREGON CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 570 OREGON BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 571 OREGON TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 572 OREGON BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 573 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 574 OREGON STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 575 OREGON STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 576 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 577 OREGON EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 578 OREGON NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 579 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 580 OREGON INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 581 OREGON PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 582 OREGON KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 583 OREGON CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 584 OREGON CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 585 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 586 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 587 OREGON SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 588 OREGON DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 589 OREGON PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 590 OREGON RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 591 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 592 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 593 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 594 NEVADA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 595 NEVADA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 596 NEVADA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 597 NEVADA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 598 NEVADA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 599 NEVADA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 600 NEVADA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 601 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 602 NEVADA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 603 NEVADA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 604 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 605 NEVADA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 606 NEVADA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 607 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 608 NEVADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 609 NEVADA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 610 NEVADA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 611 NEVADA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 612 NEVADA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 613 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 614 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 615 NEVADA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 616 NEVADA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 617 NEVADA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 618 NEVADA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 619 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 620 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 621 REST OF MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 622 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 623 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 624 NORTHEASTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 625 NORTHEASTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 626 NORTHEASTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 627 NORTHEASTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 628 NORTHEASTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 629 NORTHEASTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 630 NORTHEASTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 631 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 632 NORTHEASTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 633 NORTHEASTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 634 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 635 NORTHEASTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 636 NORTHEASTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 637 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 638 NORTHEASTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 639 NORTHEASTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 640 NORTHEASTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 641 NORTHEASTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 642 NORTHEASTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 643 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 644 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 645 NORTHEASTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 646 NORTHEASTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 647 NORTHEASTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 648 NORTHEASTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 649 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 650 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 651 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 652 NEW YORK IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 653 NEW YORK MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 654 NEW YORK ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 655 NEW YORK CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 656 NEW YORK BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 657 NEW YORK TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 658 NEW YORK BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 659 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 660 NEW YORK STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 661 NEW YORK STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 662 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 663 NEW YORK EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 664 NEW YORK NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 665 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 666 NEW YORK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 667 NEW YORK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 668 NEW YORK KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 669 NEW YORK CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 670 NEW YORK CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 671 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 672 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 673 NEW YORK SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 674 NEW YORK DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 675 NEW YORK PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 676 NEW YORK RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 677 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 678 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 679 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 680 PENNSYLVANIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 681 PENNSYLVANIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 682 PENNSYLVANIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 683 PENNSYLVANIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 684 PENNSYLVANIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 685 PENNSYLVANIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 686 PENNSYLVANIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 687 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 688 PENNSYLVANIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 689 PENNSYLVANIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 690 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 691 PENNSYLVANIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 692 PENNSYLVANIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 693 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 694 PENNSYLVANIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 695 PENNSYLVANIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 696 PENNSYLVANIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 697 PENNSYLVANIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 698 PENNSYLVANIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 699 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 700 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 701 PENNSYLVANIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 702 PENNSYLVANIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 703 PENNSYLVANIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 704 PENNSYLVANIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 705 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 706 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 707 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 708 NEW JERSEY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 709 NEW JERSEY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 710 NEW JERSEY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 711 NEW JERSEY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 712 NEW JERSEY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 713 NEW JERSEY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 714 NEW JERSEY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 715 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 716 NEW JERSEY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 717 NEW JERSEY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 718 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 719 NEW JERSEY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 720 NEW JERSEY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 721 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 722 NEW JERSEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 723 NEW JERSEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 724 NEW JERSEY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 725 NEW JERSEY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 726 NEW JERSEY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 727 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 728 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 729 NEW JERSEY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 730 NEW JERSEY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 731 NEW JERSEY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 732 NEW JERSEY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 733 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 734 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 735 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 736 MASSACHUSETTS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 737 MASSACHUSETTS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 738 MASSACHUSETTS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 739 MASSACHUSETTS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 740 MASSACHUSETTS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 741 MASSACHUSETTS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 742 MASSACHUSETTS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 743 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 744 MASSACHUSETTS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 745 MASSACHUSETTS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 746 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 747 MASSACHUSETTS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 748 MASSACHUSETTS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 749 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 750 MASSACHUSETTS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 751 MASSACHUSETTS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 752 MASSACHUSETTS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 753 MASSACHUSETTS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 754 MASSACHUSETTS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 755 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 756 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 757 MASSACHUSETTS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 758 MASSACHUSETTS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 759 MASSACHUSETTS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 760 MASSACHUSETTS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 761 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 762 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 763 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 764 MARYLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 765 MARYLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 766 MARYLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 767 MARYLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 768 MARYLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 769 MARYLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 770 MARYLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 771 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 772 MARYLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 773 MARYLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 774 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 775 MARYLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 776 MARYLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 777 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 778 MARYLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 779 MARYLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 780 MARYLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 781 MARYLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 782 MARYLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 783 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 784 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 785 MARYLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 786 MARYLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 787 MARYLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 788 MARYLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 789 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 790 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 791 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 792 CONNECTICUT IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 793 CONNECTICUT MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 794 CONNECTICUT ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 795 CONNECTICUT CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 796 CONNECTICUT BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 797 CONNECTICUT TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 798 CONNECTICUT BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 799 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 800 CONNECTICUT STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 801 CONNECTICUT STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 802 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 803 CONNECTICUT EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 804 CONNECTICUT NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 805 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 806 CONNECTICUT INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 807 CONNECTICUT PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 808 CONNECTICUT KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 809 CONNECTICUT CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 810 CONNECTICUT CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 811 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 812 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 813 CONNECTICUT SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 814 CONNECTICUT DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 815 CONNECTICUT PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 816 CONNECTICUT RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 817 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 818 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 819 REST OF NORTH-EASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: U.S. VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 11 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 AND 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET
FIGURE 13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 21 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022
FIGURE 22 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 23 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 24 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE
FIGURE 25 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 26 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 27 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 28 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 30 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 31 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 32 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 33 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 34 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 38 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 39 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 40 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 42 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 43 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 44 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
